Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT [non-germinomatous germ cell tumour].

Next Previous
X
Search
Trial Profile

A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT [non-germinomatous germ cell tumour].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin; Etoposide; Filgrastim; Filgrastim; Ifosfamide; Stem cell therapies; Thiotepa
  • Indications CNS cancer; Germ cell and embryonal neoplasms
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 14 Feb 2018 Biomarkers information updated
    • 28 Jul 2009 Planned end date changed from 1 May 2004 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Additional lead trial investigator (Drachtman R) added as reported by New Jersey Cancer Trial Connect record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top